Research Recommendations For Flexion Therapeutics Inc. (FLXN): Here is What You Should Know

Flexion Therapeutics Inc. (NASDAQ:FLXN) saw an upside of 62.11% on Monday to $9.37 after adding $3.59. The 5-day average trading volume is 3,965,912 shares of the company’s common stock. It has gained $9.89 in the past week. An average of 1,865,208 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,554,107.

FLXN’s 1-month performance is -9.83% or $3.36 on its low of $5.40 reached on 10/08/21. The company’s shares have touched a 52-week low of $4.30 and high of $13.66, with the stock’s rally to the 52-week high happening on 01/15/21. YTD, FLXN has lost -49.91% or -$2.13. However, the current price is down -31.41%% from the 52-week high price.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Insider Transactions

On Jul 19, 84 days have gone by since the last insider trading activity for Flexion Therapeutics Inc. (FLXN). Willwerth Christina (Chief Strategy Officer) most recently sold 3,945 shares at $6.45 per share on Jul 19. This transaction cost the insider $25,445. Chief Regulatory Officer, Wentworth Kerry, sold 3,944 shares at a price of $6.45 on Jul 19. Then, on Jul 19, Chief Business Officer Muzikant Adam sold 1,870 shares at a price of $6.45 per share. This transaction amounted to $12,062.

Valuation Metrics

Flexion Therapeutics Inc. (FLXN) has a trailing price-to-earnings (P/E) ratio of 23.00 for the broader industry and 32.57 for the sector.FLXN stock has a beta of 1.31. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 2.77.

Flexion Therapeutics Inc.’s quick ratio for the period ended June 29 was 4.30, with the current ratio over the same period at 4.60 meaning that FLXN stock is able to fulfill its debt obligations. In terms of profitability, the gross margin trailing 12 months is 78.00%. The trailing 12-month EBITDA margin is -104.82% while for the period ending June 29; Flexion Therapeutics Inc.’s operating margin was -71.20%. The firm’s gross profit as reported stood at $66.3 million against revenue of $85.55 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Flexion Therapeutics Inc.’s cash and short-term investments amounted to $23.62 million against total debt of $228.9 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected FLXN to announce -$0.5 per share in earnings in its latest quarter, but it posted -$0.44, representing a 12.00% surprise. EBITDA for the quarter stood at more than -$13.23 million. FLXN stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 266.22 million, with total debt at $228.9 million. Shareholders hold equity totaling $50.29 million

Technical Picture

Let’s look briefly at Flexion Therapeutics Inc. (FLXN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 October was 81.72% to suggest the stock is trending Overbought, with historical volatility in this time period at 255.71%.

The stock’s 5-day moving average is $6.59, reflecting a +54.26% or $3.31 change from its current price. FLXN is currently trading +55.54% above its 20-day SMA, +12.16% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +58.68% and -23.99% respectively.

Stochastic %K and %D was 39.90% and 24.15% and the average true range (ATR) pointed at 0.80. The RSI (14) points at 75.78%, while the 14-day stochastic is at 89.31% with the period’s ATR at 0.67. The stock’s 9-day MACD Oscillator is pointing at 0.55 and 0.52 on the 14-day charts.

Analyst Ratings

Analysts offering their rating for FLXN stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate FLXN as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 9 have offered a “buy” rating.

What is FLXN’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $6.00 and a high of $25.00, with their median price target at $17.00. Looking at these predictions, the average price target given by analysts is for Flexion Therapeutics Inc. (FLXN) stock is $17.10.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Hot Topics

Related Videos

Related Videos

Related Articles

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

592

100% free. stop anytime no spam